Podcasts about evusheld

The hosts discuss the current state of COVID since the end of the public health emergency, including updates on case and hospitalization rates, CDC recommendations for improving air quality, promising results on an Evusheld replacement, and vaccine plans for the fall. They also cover the latest news on the debt ceiling, and recent FDA approval of Paxlovid, the antiviral treatment for COVID. “Researchers estimated that based on COVID rates in January, Paxlovid can lead to 1,500 lives saved and 13,000 hospitalizations averted each week in the United States,” says Steven Newmark, Director of Policy at GHLF. Among the highlights in this episode: 01:23: Zoe Rothblatt, Associate Director of Community Outreach at GHLF, discusses with Steven the impacts of the debt-ceiling deal on COVID relief funds 01:45: Although health care cuts are concerning, the deal as currently constituted preserves funding for NextGen (working on the next COVID vaccines) and no cuts to Medicare or Medicaid have been made 04:11: The U.S. Food and Drug Administration granted full approval to paxlovid, a significant tool in the fight against COVID-19 05:27: Steven shares that COVID-19 is seeing a decrease across all metrics in all regions of the United States, according to the most recent surveillance data 07:19 - Steven details the new guidelines from the CDC for improved indoor air quality to reduce COVID-19 transmission 10:48: Steven announces the World Health Organization's recommendation for a one-strain booster targeting an Omicron subvariant for the fall 12:53: Zoe emphasizes the importance of staying home and using masks when sick, particularly for the immunocompromised 14:14: Steven shares studies indicating the risk of long COVID after a second infection is greatly reduced, with the risk being one in 40 for those over 16 years old and one in 165 for those under 60 years old 16:05: Zoe and Steven discuss the upcoming news about the COVID fall vaccine 16:43: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Evusheld is the FDA approved, lab created, preventative monoclonal antibody therapy. In addition to the lab-created variety of monoclonal antibodies (Evusheld), there are biologically derived monoclonal antibodies which are spun from the blood from people who are sick with COVID and administered to those who are sick with COVID to help speed their recovery. Evusheld is a protein that is designed to look like the proteins we make when we get sick. When injected, it makes a body like mine think we've already been sick which then keeps us from getting COVID. When I received it there were four vials injected as 2 shots in the buttocks every six months. I was a candidate for Evusheld because I'm so immune suppressed because of the chemotherapy I'm taking. Evusheld had Emergency Use Authorization (EUA) from the FDA. However, at the end of January, that EUA was revoked. Evusheld has been proved ineffective against the current COVID variants. Therefore, for the severely immunosuppressed, there is no longer a preventative option for avoiding COVID. The alternatives are now post-viral options Paxlovid and Molnupiravir, and monoclonal antibody treatment in the hospital or in urgent care clinics. Perhaps as this virus evolves and becomes less deadly we'll continue to see the threat decrease. Have you taken Evusheld? What factors in to your thinking about COVID these days? I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.

Sorry for my absence, my last video on YouTube was taken down. I received monoclonal antibodies. These are not the same as the antibodies given to people to treat COVID, but for COVID prevention. Monoclonal antibodies are given to folks for whom standard vaccines won't work or who are severely immune compromised. You may remember that on my last trip to Seattle I learned that while I have had 4 COVID vaccines/boosters -- I had almost no protection. My chemotherapy agent, Rituxan, keeps B cells from replicating/maturing. My community, Eugene/Springfield is about 235,000 people. We have one place administering these treatments and my wait was about a month to receive the treatment. Ours is being offered at a Hospital Infusion Center. I was given 4, 1.5ml vials of the Evusheld treatment in two injections, given in the rump. While it was quick to administer, I was kept for more than an hour to make sure that I didn't have any injection reaction, anaphylaxis, rash, etc. Not only did I not, in the coming days, I didn't even have the difficulties I've had with the vaccine -- like tenderness at the injection site, fever, flu-like symptoms, etc. The protection is similar to the vaccines in that it prevents the worst of disease and death but not great protection against the newest variants. Also, similarly, it needs to be readministered after 6 months. Are you eligible for monoclonal antibodies? Have you had them? What is your experience? I'm Annette Leonard, speaker, coach, and sick person who believes that my illnesses do not define me. If health is the absence of disease and wellness is the presence of wholeness, then no matter what your disease status, we can work toward your wellness, your wholeness. Whether or not you are ever "healthy" on paper, you can be well. Join me and others on the path back to wholeness at AnnetteLeonard.com. Whether you are a person experiencing chronic illness or are someone who loves or serves people with chronic illness I have great resources here on this channel or on my website for you.

The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted.

This was a big week for health news. We learned that the U.S. will end the COVID public health emergency in May, Evusheld is no longer authorized by the Food and Drug Administration (FDA) and the FDA is meeting about an annual COVID vaccine strategy. What does this mean for you as someone who lives with chronic illness? The Health Advocates break down the pros, cons, and questions that remain. “It just is kind of upsetting when you realize how health care can be offered so efficiently and now funds are going to be decreased and barriers are going to be put in place to access these different services. And it's upsetting to go backwards. And that declaration means we have to go backwards in care,” said Zoe Rothblatt, MPH, Associate Director, Community Outreach. Among the highlights in this episode: 01:24- Steven and Zoe introduce their first topic, President Biden informing Congress that he will be ending the United States' COVID-19 Public Health Emergency in May 02:39- Zoe and Steven explain what the ending of the Emergency status means for the public at large and the implications it may have on the health care system 05:17- Zoe shares the results of the latest COVID-19 quick poll regarding the resources our community wants to have 06:18- Zoe and Steven discuss the FDA no longer recommending Evusheld as a COVID preventative 07:36- The CDC has shared an action plan for those who have weakened immune systems 10:30- As the need for an annual COVID vaccine increases, Zoe and Steven discuss the FDA's vote to approve an annual vaccine 13:17- Zoe asks Steven how the FDA would go about implementing an annual COVID vaccine 15:36- We look how the rest of the world is planning to develop an annual COVID vaccine 16:34- Steven and Zoe share what they've learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.orgZoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email.See omnystudio.com/listener for privacy information.

AMA Board Chair Sandra Fryhofer, MD, AMA's liaison to the Advisory Committee on Immunization Practices (ACIP), and a member of ACIP's COVID-19 Vaccine Workgroup, recaps the latest news from the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting. Topics include the vote on “harmonizing” strain composition for both COVID-19 primary vaccines and booster shots, as well as an update about the preliminary stroke risk signal for seniors who received a Pfizer booster. American Medical Association CXO Todd Unger hosts.

We haven't been live streaming or podcasting for a few weeks so this is our chance to catch up on developments and there have been quite a few! Expert panel on hand to tell us about an imminent NICE decision and the factors that might influence the direction they go in, plus how it feels to be getting Evusheld on a trial.

-FDA is coming for my CBD gummies - https://www.cnn.com/2023/01/26/health/cbd-new-regulation-fda/index.html?utm_medium=social&utm_source=twCNN&utm_content=2023-01-27T02%3A28%3A06&utm_term=link-China claps back at Yellen - https://www.reuters.com/world/africa/china-tells-us-fix-its-own-debt-problems-after-yellen-africa-remarks-2023-01-24/-FDA pulls Evusheld authorization - https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-withdraws-authorization-astrazenecas-evusheld-2023-01-26/-29yo woman fakes birth certificate to go back to high school - https://www.cbsnews.com/news/hyejeong-shin-29-arrested-fake-birth-certificate-high-school-freshman-new-brunswick-new-jersey/-Politicians have to actually show up to work again - https://www.businessinsider.in/politics/world/news/house-speaker-kevin-mccarthy-finally-won-his-battle-against-letting-members-vote-remotely-it-could-cost-him-critical-gop-votes-when-he-needs-it-most-/amp_articleshow/97357699.cms-Video on vaccine adverse events - https://twitter.com/TheChiefNerd/status/1618739451878080512 Hosted on Acast. See acast.com/privacy for more information.

As we start the new year with a “tripledemic” from the combined threat of RSV, flu, and COVID-19, there's both a sense of hope and concern. There's hope that flu and RSV surges are now declining after a peak earlier in the season and there's concern among the immunocompromised community that the general public has moved on and are no longer taking COVID-19 safety precautions. "It's January. January is a time when viruses tend to promulgate. We're certainly in the midst of another wave when it comes to COVID, and if you want to stay safe, you're going to have to keep a mask on. A nice, good, tight-fitting mask, whenever you're in public,” says Steven Newmark, Director of Policy at GHLF. “And, unfortunately, there aren't too many other ways to mitigate [risk] in our society." Among the highlights in this episode: 2:33: As society moves on and fewer precautions are being taken to fight the COVID-19 pandemic, flu season started early in the U.S. this year 3:28: Cases of respiratory syncytial virus, or RSV, have been declining 3:56: At its peak, in mid-November of 2022, new RSV hospitalizations reached an all-time high of 70 children hospitalized per 100,000 infections. Historically, peaks have been anywhere between 26 and 52 children per 100,000 infections 5:02: “Another thing that's somewhat positive, the severity of the flu this year is not particularly high. They are on track for a mediocre season when it comes to hospitalizations. So that's a good thing as well, of course, and not to minimize what is happening out there. We've already lost 13,000 Americans to the flu this season. 61 of those were children,” says Steven Newmark 5:58: There is a high possibility that a second flu strain could be coming our way 7:37: Omicron subvariants continue to spread, especially the subvariant XBB.1.5 which seems to be circumventing immunity from vaccination and infection 9:38: “I know our chronic disease community really is there for each other, and it's amazing to have that support, but it's not as strong with the general public. So as we're in this new year, and people continue to get over COVID, I just want to say that… we're here for you and we understand you and we're going to keep talking about and providing tips and health advocacy for… fighting this virus together!” says Zoe Rothblatt, Associate Director of Community Outreach at GHLF 10:32: A recent study shows those who were vaccinated and received a bivalent booster have an 18.6 times lower risk of dying from COVID-19 compared to those who were unvaccinated. The risk of infection is also three times lower when people are vaccinated. 11:05: Monoclonal antibodies, including Evusheld, have lost potency against new omicron subvariants 12:18: “There are a lot of people out there getting sick, and there is still plenty of winter season left. As a listener of this podcast, you know what to do: make a plan with your doctor, make a plan with your family, make a plan for yourself and be ready,” says Steven 12:46: The impact of the new congress on legislation work 13:12: The Safe Step Act remains one of the legislative priorities for GHLF in 2023 15:15: Could the results of the mid-term elections have an impact on COVID funding? 16:37: To get involved with our advocacy work, visit 50statenetwork.org or send an email to advocacy@ghlf.org 17:49: More on GHLF's advocacy work at the state level 18:46: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

We're taking a short break over Christmas, but we thought it would be a good time to take stock and see how far we've come with the campaign to get Evusheld to the #forgotten500K. We're also casting forward to the future to see where we can take the campaign from here and we will be back early in the New Year. Enjoy

Millions of lives are at risk worldwide because of unjust systems that prevent those who are most vulnerable from getting the medicines they need. Even in the U.S., structural inequities exist and remain prevalent, despite appeals for their elimination. In this episode, Priti Krishtel, a health justice lawyer and Co-Founder and Co-Executive Director of the non-profit organization I-MAK, shares how her organization advances solutions to address structural inequity in the medicines system through research, education, and policy. “I think in the U.S. we have a real problem now. And that's why so many people are speaking out to say prescription drugs should not be priced this high,” says Priti Krishtel. Among the highlights in this episode: 1:40: Listener comment 2:39: Twitter is no longer enforcing its COVID misinformation policy 3:50: “Misinformation that spreads on the internet, particularly a place like Twitter, can reach millions of people in a matter of seconds, let alone minutes and days, and influential people who have influence over others, people who are respected and looked up to, start to spread this misinformation as well,” says Steven Newmark, Director of Policy at GHLF 4:13: GHLF has developed a free program for patients and their families to access updated and verified information, community support, and other resources tailored specifically to their health and safety. You can enroll in the program here: https://ghlf.org/coronavirus-patient-support/ 5:08: In a recent statement, the National Institutes of Health (NIH) noted that COVID-19 subvariants are likely to be resistant to Evusheld, a preventive COVID treatment for people who are immunocompromised 5:56: As treatments like Evusheld become less powerful in preventing COVID-19, other measures like getting the new bivalent vaccine booster are even more crucial for immunocompromised patients 6:06: December 1 through December 7 marks Crohn's and Colitis Awareness Week 8:06: Priti Krishtel shares what drew her to found I-MAK and describes the mission of the organization 9:33: “We were working in the Global South… in middle income countries that have really huge populations living in poverty… And there we saw a lot of wins,” says Priti Krishtel. “But then in about 2015, we started getting calls from the United States because you know, prescription drugs spending, I think, has increased about 60% over the last 10 years in the U.S.” 12:22: I-MAK's Participatory Changemaking tool (PCM) and an explanation of how it brings together members of affected communities as well as leaders from government, academia, and the private sector to create new thinking about the future of the patent system 14:21: Priti Krishtel shares a memorable patient interaction and its impact on her 17:09: To learn more about what's happening with patent reform, you can sign up for I-MAK's newsletter at i-mak.org 17:39: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Missing novel Covid treatments and cutting edge pharma tech? Well, don't worry because Evusheld is the newish monoclonal antibody thing that might be useful as a prophylactic treatment for those people for whom vaccines don't work. But how do we know what do we know, what don't we know, and how can we make this all comprehensible if someone asks us about it?

There has been so much to worry us in recent weeks but now some good news on the horizon , with the advent of a new clinical trial which will combine the use of Evusheld with vaccinations for immunocompromised patients. We speak to the trial's lead, Mark Tuthill and the panel responds to some of your questions and concerns.Hope you find it useful!

In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:COVID-19 vaccines, including omicron BA.1 bivalent boosterRisk factors for breakthrough COVID-19 infectionsCOVID-19 diagnostics, including digital droplet PCRCOVID-19 therapeutics, including:Nirmatrelvir plus ritonavirTixagevimab plus cilgavimabBaricitinibTocilizumabInhaled interferon β-1aCOVID-19 therapeutics and outcomes in patients with immunocompromiseLong COVIDPresenters:Princy N. Kumar, MD, FIDSA, MACPProfessor of Medicine and MicrobiologyChief, Division of Infectious Diseases and Travel MedicineSenior Associate Dean of StudentsGeorgetown University School of MedicineWashington, DCPaul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the downloadable slideset at:http://bit.ly/3gkJI67Link to full program:http://bit.ly/3TSVthM

The waiting goes on but the campaign and the science continues amidst encouraging signs. The prestigious US publication @TIME hails Evusheld, the antibody treatment, as one of the best innovations of the year. And Dr Lennard Lee introduces us to the people who have helped him with a new report showing encouraging stats.All that and a bit of patient politics!

A solution is out there for those who need an antibody treatment for Covid protection but it's far from simple and not for everyone. As #theforgotten500K await a government rethink on rolling out Evusheld free in the NHS, desperate decisions are being made. Some are having to decide whether they have the finances to pay privately and that means much soul-searching. For patients without the cash they can only wait and hope that a decision will be made before Christmas.So what's it like to have to weigh up the options? We hear from three patients and the wife of one who tell us what they've had to take into account and what it's cost them financially and emotionally.

This edition of Ripples was originally played out live stream on Twitter spaces so this is my opportunity to let Ripples podcast listeners hear the panel talk about the impact that the recent Westminster vigil had on the debate to get Evusheld , an antibody treatment rolled out free via the NHS, for #theforgotten500K.

This week's been a whirlwind of activity- many of us have watched the shenanigans at Westminster through our fingers. We lost a Prime Minister and we're about to get another one ..,but despite the political turmoil, a campaign calling for the rollout of Evusheld to protect #theforgotten500K blasted its way onto the agenda on Monday morning. Will it change how the UK and devolved. governments act on a roll out? We hear from a senior Scottish Labour MSP. Huge thanks due to Daisy Cooper MP for allowing us to use a key part of her speech at Westminster!

In this special episode we reveal the ongoing crisis being endured by the Forgotten 500,000 … those British people whose compromised immune systems mean they live in constant fear of infection, serious illness or death. For a large number of those men, women and children lockdown has never ended because of a government refusal to act. You'll hear a shocking first-hand account from English Professor Martin Eve, who is now entering the 134th week of isolation at home. He's joined by Dr Lennard Lee – a leading NHS oncologist who is campaigning with Martin to bring an end to this appalling situation. They want to see the introduction of the Cambridge made drug Evusheld which acts as a barrier against infection, allowing patients to live more normal lives. Although Evusheld has been exported and is being used successfully in 32 countries, it is being denied to people living here in the UK. This is the story of a crisis that has been out of sight and out of mind for too long. Please support the campaign if, after listening to this episode, you agree it's time to act.Martin's Crisis Cures:1st Crisis Cure – Providing a home for an unwanted pet: I found comfort in adopting an older dog from a shelter.2nd Crisis Cure – Making music and creative writing: Creativity offers a fantastic therapeutic outlet and can put you back in control.3rd Crisis Cure – Technology: Dependence on technology whilst I continue to shield gives me invaluable access to the people I love.Links:Campaign website – https://getevusheld.uk/500k/Write to your MP here (letter templates available) – https://www.writetothem.com/Sign the petition here – https://petition.parliament.uk/petitions/611884Full episode transcript available at: https://www.crisiswhatcrisis.com/podcasts/britains-lockdown-shame-the-story-of-the-forgotten-500k/ Stream/Buy ‘Allies' by Some Velvet Morning: https://ampl.ink/qp6bm Some Velvet Morning Website: www.somevelvetmorning.co.ukYour Daily Practice: Sleep by Myndstream: https://open.spotify.com/track/5OX9XgJufFz9g63o2Dv2i5?si=b2f9397c92084682Host– Andy CoulsonProducer – Louise Difford

We decided to try something slightly different on the podcast this week -in fact we hopped over to Twitter spaces to do a live stream following Daisy Cooper's Parliamentary debate in which she asked the government to reconsider their position on Evusheld, a treatment that could help protect those who have been shielding for 2 1/2 years. It's an unedited recording… just how it happened… with a fantastic panel of patients, campaigners and scientist.Hope you enjoy it!

Here are the links for everything discussed in Episode 82. Times are also below so feel free to skip around and get to the updates that interest you.  (1:10) FDA adds new indication for Boostrix vaccine (6:44) FDA updated the authorized fact sheet for Evusheld PAXLOVID Patient Eligibility Screening Checklist Tool for PrescribersCDC website for COVID information - get boosted!FDA monkeypox response websiteConnect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Patients groups and charities are leading the charge to help support the #forgotten500k - long term shielders who are still not protected against COVID.#Evusheld is being rolled out in 30+ other nations. Why not here in the UK?

ALS treatment news; Evusheld fact sheet update; an at-home epilepsy diagnostic aid gets cleared; drug recalls; and a laser therapy for fibromyalgia.

Tune in as we discuss the PROVENT trial and the on-going TACKLE trial to determine whether or not Evusheld can increase cardiovascular events.

OPTICS pharmacist Chris Bender is back for a rundown of a some timely COVID-19 clinical topics. We discuss the Novavax vaccine, the anticipated rollout of fall booster shots, the use(or underuse)of Evusheld, the Paxlovid rebound, and more. Chris also takes a moment thoroughly go over all the current clinical guidance for booster shots. Recorded 8.12.2022 Link to CDC guidance for booster shots: www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html

  Vidcast:  https://youtu.be/9yjeL3pYS-4   Metformin, ivermectin, and fluvoxamine, 3 drugs in current use for other conditions, offer no help when taken for CoVid infections in non-hospitalized patients.  This the conclusion of a definitive doubled-blind, randomized, placebo-controlled collaborative study headed by researchers at the University of Minnesota.   A total of 1431 patients participated.  Their median age was 46 years, 56% were female, 6% were pregnant, and 52% had been vaccinated.  The data analysis showed that these 3 drugs, metformin, ivermectin, and fluvoxamine failed to prevent CoVid-driven lung infections with low blood oxygenation, ER visits, hospitalizations, or death.   If you do contract CoVid and are at risk for serious disease, know that there are effective agents to stop the virus from landing you in the hospital or in a coffin.  Taken as soon as possible after a CoVid diagnosis, Paxlovid taken orally and remdesivir administered intravenously are viral polymerase inhibitors that block CoVid replication in those with early infections. For those with more severe and persistent infections, intravenously administered monoclonal antibodies that block viral entry into human cells as a group have less effectiveness against the current Omicron sub-variant BA.5.  One monoclonal antibody, bebtelovimab, and the monoclonal antibody cocktail of 2 monoclonal antibodies, Evusheld, do work against BA.5 and can be used for outpatient and hospitalized CoVid patients.   https://www.nejm.org/doi/full/10.1056/NEJMoa2201662?query=TOC&cid=NEJM%20eToc,%20August%2018,%202022%20DM1352386_NEJM_Non_Subscriber&bid=1120617993   #covid #paxlovid #monoclonalantibodies #bebtelovimab #evusheld #ivermectin #metformin #fluvoxamine  

Women are roughly 3 times more likely to develop MS compared to men. But when men develop MS, they're more likely to experience a more aggressive disease course. Men are more likely to experience motor problems, loss of coordination and balance, and cognitive difficulties. When they experience a relapse, men are more likely to see their exacerbated symptoms continue, even during times of remission. Given these evidence-based observations, it seems sadly ironic that, as they develop MS symptoms, men are less likely to seek medical care or even a diagnosis. Dr. Robert Shin returns to the podcast to demystify some of the riddles surrounding men and MS. Dr. Shin is a Professor in the Department of Neurology at MedStar Georgetown University Hospital, and the Director of the Georgetown Multiple Sclerosis and Neuroimmunology Center. We're also sharing the registration details for the National MS Society's webcast, What Does the New Drug Pricing Law Mean to You?. The webcast takes place this Thursday, and you won't want to miss it. We'll tell you about a study that may have identified an imaging biomarker that can predict future MS progression. (And we'll explain why that can make a huge difference in your MS treatment plan) We'll share some discouraging news about the availability of Evusheld in the U.K. We'll point you toward Elizabeth Jameson's Washington Post editorial that explains how learning to swear can be therapeutic for someone living with progressive MS. And we'll share results from a Cleveland Clinic study that shows how a man's own definition of masculinity can get in the way of his MS treatment. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: MS and Men  :22 Find out how and when the Inflation Reduction Act will impact the cost of your prescription drugs  1:41 Study demonstrates that thinning of retinal layers predicts future MS disability  2:35 U.K. opts not to buy Evusheld  5:17 Elizabeth Jameson learns the value of a well-intentioned F-bomb  6:35 Study shows how masculine ideals drive healthcare decisions for men with MS  8:39 Dr. Robert Shin discusses the specifics associated with Men and MS  12:52 Share this episode  30:56 Download the RealTalk MS app for your iOS or Android device   31:16 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/260 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance Registration for National MS Society Webcast: What Does the New Drug Pricing Law Mean to You? https://nmss.zoom.us/webinar/register/WN_auRCXBi2TGCgzHeV1CWMkw STUDY: Retinal Thinning After Optic Neuritis is Associated with Future Relapse Remission in Relapsing Multiple Sclerosis https://neurology.org/content/early/2022/08/01/WNL.0000000000200970 Elizabeth Jameson in the Washington Post: How I Learned that Swearing Can Be Good for the Soul https://wapo.st/3vpRJeo STUDY: Effects of Conformity to Masculine Norms and Coping on Health Behaviors in Men with Multiple Sclerosishttps://doi.org/10.7224/1537-2073.2020-116 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 260 Guest: Dr. Robert Shin Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy  

Coverage of major news stories 1. Yoon Back to Work 2. Chip 4 3. Trip to China 4. Food Prices 5. Evusheld

In his weekly clinical update Dr. Griffin discusses Tecovirimat for treatment of monkeypox, the safety and acceptance of vaccination after multisystem inflammatory syndrome, variants in solid organ transplant recipients, masks for prevention of respiratory virus infections, pre-exposure prophylaxis with Evusheld, the association between Evusheld administration and infection,  if repeat administration of casirivimab and imdevimab is well-tolerated, viral and symptom rebound in untreated infection, extended Remdesivir infusion for persistent infection, Baricitinib in patients admitted with infection, and cognitive impairment 13 months after hospitalization. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Armchair Expert with Malcolm Gladwell Tecovirimat for treatment of monkeypox (OFID) Safety and acceptance of vaccination after MIS (JPID) Is variant less virulent in solid organ transplant recipients (Transplant Infectious Disease) Masks for prevention of respiratory virus infections (Annals of Internal Medicine) Pre-exposure prophylaxis with Evusheld (CMI) Association between Evusheld administration and infection (CID) Repeat administration of casirivimab and imdevimab well-tolerated (ISID) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) Viral and symptom rebound in untreated infection (medRxiv) Extended Remdesivir infusion for persistent infection (OFID) Baricitinib in patients admitted with infection (The Lancet) Cognitive Impairment 13 months after hospitalization (OFID) Contribute to Floating Doctors fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 924 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Will a drug called Evusheld cut Covid deaths still further? Is the Arab Spring over? And are we ready for the return of reality TV? Olly Mann and The Week delve behind the headlines and debate what really matters from the past seven days. With Tom Chivers, Arion McNicoll and Sorcha Bradley

For people living with rheumatoid arthritis, knowledge is power, whether it's here in the United States or around the world. In this episode, learn how a leading health advocate in the UK is serving 450,000 adults living with RA and 12,000 children with juvenile rheumatoid arthritis. “Everything we do is about giving the individual living with inflammatory arthritis as much knowledge and as many tools for them to understand their condition,” says Clare Jacklin, CEO at National Rheumatoid Arthritis Society in the United Kingdom. Among the highlights in this episode: 1:06: Listener comment 1:40: The U.S. is working to increase access to Evusheld, the preventative COVID treatment to help protect the immunocompromised against COVID 2:37: President Biden tested positive for a rebound case of COVID-19 after being treated with Paxlovid, the antiviral treatment 3:56: The National Rheumatoid Arthritis Society is “the only patient organization in the United Kingdom that focuses specifically on rheumatoid arthritis,” says Clare 5:41: Clare describes the changes she's seen for rheumatology patients in her 15 years advocating for the organization 7:43: Clare shares what she and other advocates learn by attending the European Conference on Rheumatology 9:53: The ways Clare's organization keeps  rheumatoid arthritis patients up-to-date with the latest health information 11:43: “I think the key thing about being an advocate for yourself is really to have the knowledge and knowledge is power,” believes Clare 13:03: Clare describes ways, big and small, that her organization helps patients 15:27: Clare provides an update on COVID in the UK: “I wouldn't say our community feels safe. But we feel safer than we did two years ago” 17:28: What our hosts learned from this episode Learn more about Clare's organization, National Rheumatoid Arthritis Society in the United Kingdom  Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Will a drug called Evusheld cut Covid deaths still further? Is the Arab Spring over? And are we ready for the return of reality TV? Olly Mann and The Week delve behind the headlines and debate what really matters from the past seven days. With Tom Chivers, Arion McNicoll and Sorcha Bradley

Paxlovid, Evusheld, steroid puffers. Callers who've fallen ill want to know how to treat COVID-19 now. Infectious disease specialist Dr. Zain Chagla answers questions.

Whether we adults admit it or not, kids see everything. That includes seeing a parent or other family member who's living with MS. And because kids don't have an understanding of neurological conditions, they use their imaginations to fill in the blanks. That can very quickly take them down a rabbit-hole that's far scarier than the reality of living with MS. So, when do you talk to your kids about MS? And what do you say? Licensed social worker and behavioral specialist Erin Martin joins me to talk about talking to kids about your MS. If you're living with MS and you still smoke, we're sharing results of a study that you may want to carefully consider. We'll also share the results of two different studies that might help inform your COVID-19 strategy if you're on a b-cell depleting disease-modifying therapy. We'll let you know how you can catch the video replay of an excellent webinar presented by the International Progressive MS Alliance. We'll share the details about how a group of international experts discovered a method for measuring remyelinated MS lesions (And we'll tell you why that's become important right now) We'll also share some encouraging results of a study that looked at the impact of estriol and Copaxone on women living with MS. We have a lot to talk about! Are you ready for RealTalk MS??! Talking to kids about MS   :22 Smoking is shown to affect MS progression  1:29 COVID-19 vaccines, breakthrough infections, and Evusheld  3:44 Catch the video replay of the International Progressive MS Alliance Webinar  8:31 A team of international experts discover a way to measure myelin repair  9:08 Combination of Estriol plus Copaxone is shown to reduce neurofilament light chain levels  11:57 Behavioral specialist Erin Martin discusses talking about MS with your kids  14:27 Share this episode  29:03 Download the RealTalk MS app for your iOS or Android device   29:24 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/254 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance STUDY: The Effect of Smoking on Long-Term Grey Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis https://nn.neurology.org/content/9/5/e200008 STUDY: Tixagevimab and Cligavimab (Evusheld) Boost Antibody Levels to SARS-COV2 in Patients with Multiple Sclerosis on B-Cell Depleters https://sciencedirect.com/science/article/pii/S2211034822004163 VIDEO: Solving the Mystery of Progression: The Key to New Treatments for Progressive MS https://youtube.com/watch?v=U5sm54HSBpY STUDY: A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis https://onlinelibrary.wiley.com/doi/10.1002/ana.26441 STUDY: Decreased Neurofilament Light Chain Levels in Estriol-Treated Multiple Sclerosis https://onlinelibrary.wiley.com/doi/10.1002/acn3.51622 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 254 Guest: Erin Martin Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Pharmacists now allowed to prescribe Paxlovid; new dosing recommendations for Evusheld; abuse-deterrent opioid analgesic; priority review for early alzheimer disease treatment; morphine tablets recalled.

New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.

รัฐบาลไทยเตรียมความพร้อมการผ่อนปรนมาตรการป้องกันโควิดและรายละเอียดมาตรการอื่นๆ พร้อมฟังประเด็นอย.เตรียมวางแผนใช้ยา Evusheld

16.00 อย.อนุมัติใช้ยาฉีด Evusheld ป้องกันโควิด 19 ในภาวะฉุกเฉิน ตั้งแต่อายุ 12 ปีขึ้นไป พบสามารถป้องกันติดเชื้อ ป่วยหนัก และเสียชีวิตในผู้ป่วยภูมิคุ้มกันบกพร่อง 3 กลุ่ม

Multiple Sclerosis News Today's multimedia associate, Price Wooldridge, discuses how Evusheld was found to boost immune responses against COVID-19 among vaccinated multiple sclerosis patients. He also reads the new Expert Voices installment, in which Dawn Ehde, PhD, answers questions about pain management for people with multiple sclerosis. =================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

I'm recently back from seeing my team of specialists up in Seattle. I go up to UW several times a year to consult about my lung disease. This trip I was able to consult with a rheumatologist who treats other patients with antisynthetase syndrome. As you know I take Rituxan (Rituximab, Ritux) as an infusion for my autoimmune disease. Part of how it works is it kills and keeps B cells from maturing. The COVID vaccine (and other MRNA vaccines) rely heavily on B cells to replicate and produce the autoantibodies that make the vaccines effective. While I've had 4 COVID vaccines at this point, I've been told to understand that they likely have limited effectiveness because of the Rituxan treatments I receive in an ongoing way. In Seattle, the consulting rheumatologist decided to test my blood for COVID antibodies to see what protection the vaccines have given me. I was warned that the labs might be confusing to understand and therefore, he said, "if you Spike Ig number is less than 1000," you have way too little protection and you should get monoclonal antibody treatment. When I read the labs the following day, my number was 5.7!!!! That number is so low, it looks like I've never had a vaccine much less four. I am, of course, a candidate for Evusheld, the monoclonal antibody treatment. Are you on an immune modifying drug? If so, get your doctor to test your antibodies? There are new ways to protect yourself. Have you had Evusheld? Are you on Rituxan and been taking COVID vaccines? Tell me about your experiences. Book giveaways: I'll be having a drawing to give away two books. One is "My Pain Body Solution," by Michael J Murray, (https://greenleafbookgroup.com/titles/my-pain-body-solution) the other is "Walking on Pins and Needles," by Arlene Faulk (https://www.bookcellarinc.com/walking-pins-and-needles). Here's how to enter: 1) Leave me a rating or review on whatever audio podcast platform you listen to. 2) Let me know you've done that by emailing me at hello@annetteleonard.com or leaving me a comment about it on YouTube so that you can be entered in to the drawing. If you have a preference about which book you'd like, let me know in your comment or email. 3) If you'd like to be entered multiple times you can also post about one (or both of the books) and tag me on Instagram @theAnnetteLeonard including tag of either @arlenefaulk or #mypainbodysolution, for up to two additional entries. The drawing is planned for 6/30 for Arlene Faulk's book and 7/5 for Mike Murray's.

Evusheld is one of the newest preventative medicine approved by Health Canada against COVID-19. Unlike a vaccine, Evusheld is a prophylactic tool that contains antibodies and protect individuals who cannot get vaccinated or are immunocompromised.

Hospital Malpractice, WHO caught lying AGAIN. Clark Clay has discovered an NTI document that corresponded with a MONKEYPOX simulated outbreak test a YEAR ago. Do we have information on Evusheld? Do Spike Proteins transmit via touch? Is MonkeyPox growing because of VAIDS passed on to Vaccinated people? Dr. Jane Ruby answers these questions & more on Ask Dr. Jane Wednesday! Rod and Vira Brooks need your help. Rod was put under Remdesivir treatment without consent and is now holding on to life. They are now facing over $200 thousand in debt, and eviction on July 31st. Give that hospital Hell: St. Luke's In Milwaukee Wisconsin 2900 west Oklahoma avenue 414-649-6000 DONATE TO THEIR GIVE SEND GO: https://www.givesendgo.com/G394K/donate Don't miss a moment of Wednesday's edition of the Stew Peters Show, live on StewPeters.com Don't forget to also check out DominanceOnDemand.com for help on increasing your mental & physical strength to battle the deep-state's KRYPTONITE plot on Americans! Visit our friends at Goldco! Call 855-706-GOLD or visit http://goldco.com/SP Get Dr. Zelenko's Anti-Shedding Treatment, NOW AVAILABLE FOR KIDS: http://zStackProtocol.com Go Ad-Free, Get Exclusive Content, Become a Premium user: https://redvoicemedia.com/premium Follow Stew on Gab: https://gab.com/RealStewPeters See all of Stew's content at https://StewPeters.TV Watch full episodes here: https://redvoicemedia.net/stew-full-shows Check out Stew's store: http://StewPeters.shop Support our efforts to keep truth alive: https://www.redvoicemedia.com/support-red-voice-media/

It's been a while since we've done a Covid/bioethics podcast (see prior ethics podcasts here, here, here, and here).  But Covid is not over and this pandemic keeps raising challenging issues that force us to consider competing ethical considerations.   This week, we discuss an article by bioethicists Govind Persad and Emily Largent arguing that the NIH guidance for allocation of Paxlovid during conditions of scarcity.  They argue that the current guidelines, which prioritize immunocompromised people and unvaccinated older people on the same level, should be re-done to prioritize the immunocompromised first, and additionally move up older vaccinated individuals or vaccinated persons with comorbidities.  The basis of their argument is the ethical notion of “reciprocity” - people who are vaccinated have done something to protect the public health, and we owe them something for taking that action.  Eric and I attempt to poke holes in their arguments, resulting in a spirited discussion. To be sure, Paxlovid is no longer as scarce as it was a few months back.  But the argument is important because, as we've seen, new treatments are almost always scarce at the start.  Evusheld is the latest case in point.  Sometimes, you can't always get what you want… -@AlexSmithMD

It's been roughly six months since AstraZeneca released a COVID-19 antibody treatment called Evusheld, designed for immunocompromised people. But a lack of outreach and unequal distribution has led to a complicated and confusing rollout — leaving millions of vulnerable Americans without protection. Plus, what experts look for in the minutes from Federal Reserve meetings and how high energy prices please investors but burden the economy.

It's been roughly six months since AstraZeneca released a COVID-19 antibody treatment called Evusheld, designed for immunocompromised people. But a lack of outreach and unequal distribution has led to a complicated and confusing rollout — leaving millions of vulnerable Americans without protection. Plus, what experts look for in the minutes from Federal Reserve meetings and how high energy prices please investors but burden the economy.

The last time we talked with Dr. Peter Chin-Hong, it was Dec 2020. Now, it's May 2022 — 17 months later. A lot has changed and in some ways it feels like nothing has changed. This time around, we get into current details around coronavirus/COVID, what's happening now/the current state, and what the future looks like. We recorded this episode over two sessions and along the way we get into many topics, including the notion of reinfections (more and more common with Omicron), how the testing numbers may not reflect actual cases with more and more home testing (and some people not testing at all), how an at-home test is different than a PCR test, and the current slate of variants — BA.1, BA.2, BA2.12.1, BA.4, BA.5, XE, etc. We also touch on COVID therapies including Paxlovid, an oral antiviral treatment, and Evusheld, monoclonal antibodies. As well, we talked about some of what Dr. Chin-Hong is concerned about in the future — including avian flu and influenza along with the idea that diseases like valley fever (coccidioidomycosis) have been creeping up over the last few years because we as humans are settling into areas (more rural, for instance) that large groups of us haven't been before. And then, we end the show by talking about his work as a professor of medicine and educator at University of California, San Francisco (UCSF) — what teaching medicine has looked like the last few years with students (and teachers) as little blobs on a screen. Stay tuned until the end of the episode for a longer bit about the flu that didn't really have a place anywhere else. Special Guest: Dr. Peter Chin-Hong.

Google I/O reveals; Evusheld for COVID; Ukraine Drones; Twitter Privacy Game; Solve Wordle fast; Stopping Data Collection; Apple Cloud Settlement; Disable Ad ID on iOs; Real Cost of Electric Cars; Lego Optimus Prime; Norm MacDonald Netflix

A series of letters and numbers have changed our lives: COVID-19, SARS-CoV-2, Omicron, Delta, BA.4, BA.5. So no wonder we’re confused by the virus and all its variants. In this episode, our host Zoe Rothblatt leads our class in sorting through the confusion and, together with Steven Newmark, bottom line why we need to understand it all. “How do you recognize your symptoms? I did a COVID test because I was so nervous. I'm like, "No; it's allergies." And it would really be helpful if I read up more so I could recognize those symptoms and not bring myself into a panic,” says Zoe, Patient Advocate and Community Outreach Manager at the Global Heathy Living Foundation. Among the highlights in this episode 1:12: Listener’s feedback 1:37: How do you know the difference between a COVID subvariant and variant 2:03: COVID-19 Patient Support Program quick poll results on Evusheld, a medication to prevent COVID before exposure in immunocompromised individuals 4:03: GHLF testified before the Delaware State Senate for a bill that would ban copay accumulator adjusters 4:44: Zoe describes running out of her copay assistance 5:20: Steven recalls how it took 4 people to use his copay card at his specialty pharmacy 6:00: FDA approves Rinvoq for people with ankylosing spondylitis 6:12: New mask mandates in California and Massachusetts 6:53: Class is in session: defining the differences in mutation, strain, variant, and subvariant 10:40: We had COVID, we got a variant, the building blocks have changed 10:56: If you get infected with a particular variant, you’re less likely to be reinfected with that variant in the future 11:17: Why does it matter that we know the differences? 13:01: When you get diagnosed, it feels good to know what it’s called, explains Zoe 14:58: Hopeful signs the virus and its variants are becoming weaker 15:40: Answering listeners’ questions: "I've had one or two doses of Evusheld, now what?” 16:45: Steve and Zoe take us through their safety precautions while out in public 19:47: What our hosts Steven and Zoe learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments, or a video or audio clip of yourself, to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

KSQD 4-27-2022: The role of T-cells in the action of COVID-19 booster vaccines; Vitamin K does not cause blood clots and the different roles of vitamin K1 vs. K2; Paxlovid and EVUSHELD are antibody treatments for COVID-19 that attack the spike protein; CRISPR experiment proves a gene mutation leading to Lupus; Coronary arterial plaque, the calcium CT scan to measure it and preventative measures; AI interpretation of CT images finds pancreatic cancer better than humans alone; Oral squamous cell carcinoma is diagnosed by dentists, but one third of Americans don't see a dentist regularly; Comparisons of diets for their effects on reducing cancer progression -- probiotics also help; Somatic mutation rates in mammals define the expected lifetimes of mammalian species

KSQD 4-13-2022: COVID-19 News: Second booster is recommended , EVUSHELD and Paxlovid treatments for COVID-19; Is high dose of Biotin useful? High biotin intake can interfere with hormone test results; Vitamin K2 helps reduce visceral fat; mRNA technology and the attempt to develop oral vaccines; Edible fluorescent silk tags to identify fake drugs; Caller inquires about how much Vitamin K and Vitamin D3 he should take; A case of dry mouth and related symptoms in a 72 year old woman; A repurposed treatment helps Duchenne Muscular dystrophy; Tele-robotic operations offer quicker response time to clear clots with strokes or aneurysms; Desire for faces to match their selfie image photos via plastic surgery operations; Low sodium, high potassium diet is good for hypertension

In COVID-19 clinical update #111, Dr. Griffin discusses vaccine coverage and mortality in Hong Kong, immune response to boosters in kids, hospitalization of kids, breath based diagnostic test, viral co-infections, bivalent mRNA vaccine, intramuscular Evusheld, and global long COVID. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Vaccine coverage and mortality, Hong Kong (MMWR) Kids behind on routine vaccinations (Politico) Immune response to booster, 5-11 year olds (Pfizer) Children and vaccination (AAP) Hospitalization of 5-11 year olds (MMWR) Test using breath samples (FDA) Influenza virus, adenovirus, RS virus co-infections (Lancet) Booster crystal ball (TWiV 890) Bivalent vaccine (Res Square) Bivalent vaccine in mice (bioRxiv) Intramuscular Evusheld (NEJM) Global PASC (J Inf Dis) Dr. Griffin's treatment guide (pdf) Letters read on TWiV 892 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Additional resources OHA COVID-19 vaccine website: covidvaccine.oregon.gov OHA Facebook  Safe+Strong website Ask a Black Doctor on The Numberz REACH webpage and REACH Facebook Treatments for COVID-19 Q1: I have heard that some people can get treated for COVID-19. What treatments are available and how are they different from vaccines? Yes – treatments for COVID-19 are available for some people. Some treatments are given in the hospital, some are infusions and some are pills you can take at home. They are all in short supply and currently available to people who are high risk of severe disease.  Vaccines introduce your immune system to a protein from the virus, allowing you to build up antibodies without being infected. Vaccination can also boost any natural immunity a person may have from being previously infected.  When somebody with sufficient antibodies is exposed to COVID-19, they immediately fend off the virus, which prevents infection. As antibody levels drop, the virus may be able to infect the person but the immune system still has a decent chance to fight COVID-19 and prevent severe infection.  Booster shots rebuild antibodies quickly, within a few days, even quicker than the original vaccination. This rapid rebuild also happens when an unvaccinated person previously infected with the COVID-19 virus gets their first vaccination. So be sure to get vaccinated and boosted, even if you have previously been infected with COVID-19. Treatments do not replace vaccination, which remains the most important step we can take to protect ourselves and our loved ones.  If someone can't get vaccinated, there is a treatment available that helps the body fight the virus that causes COVID-19.  Treatment for COVID-19 must take place shortly after someone has tested positive. If you've tested positive for COVID or have symptoms, contact your doctor right away. Q2: Someone was telling me about the federal Test to Treat program. Is this a program for everyone? The Test to Treat program connects people that are at high risk of severe illness from COVID-19 with the right treatment. It provides people a place to go to get tested, receive a prescription for a treatment, and fill that prescription all at one location. The program is intended for people that do not have a doctor or who cannot easily get in to see their doctor. However, anyone can receive treatment at a Test to Treat site. To participate, a person can use the Test to Treat Locator to find a site, or call 1-800-232-0233. These sites receive their therapeutics from the federal government. OHA is working on adding additional sites that fit federal criteria to be a Test to Treat site.   Q3: If treatments support defense against COVID-19, why aren't they available to everyone? There a few reasons why treatments are not available to everyone. First, vaccines have proven to be the best defense against COVID-19. Get vaccinated and then boosted. Also, don't forget your flu shot. Secondly, because of nationwide shortages, treatments are not widely available. Finally, it is all based on eligibility. A healthcare provider determines eligibility based on your medical profile. They will consider things like if you cannot get vaccinated due to health conditions or if you had a bad reaction to the vaccine or if you need additional treatment due to a weakened immune system. Only a healthcare provider can assess if you are eligible. Q3: Are treatments safe?  Depending on your medical history, certain treatments are not recommended. To determine which treatment is right for you, consult your doctor. You should also always check that your information is from a trusted source. If you have questions about any medication, contact the FDA's Division of Drug Information at 301-796-3400 or druginfo@fda.hhs.gov. Q5: What are the names of the FDA approved or authorized treatments and once I take them, how do they work in my body to fight COVID-19? The FDA has authorized two oral antiviral medications, one from Pfizer named Paxlovid. The other from Merck named Molnupiravir. With either one, they must be taken as soon as possible after a positive COVID-19 test and within the first five days of symptoms to be effective.  Paxlovid works by stoping the replication of the COVID-19 virus in the body by binding to an enzyme that disrupts the virus' ability to mutate and keeps certain viral proteins from forming correctly.   Molnupiravir interrupts replication of the virus' genetic material by introducing mutations. As the virus copies itself, it gets so mutated that it can no longer function.   The same thing happens with the FDA approved antiviral drug Remdesivir, known as Veklury, it also acts on the virus' genetic material, blocking its ability to mutate. It is administered by injection into the vein through an IV. Monoclonal antibodies (mAbs) are authorized for use to treat COVID-19. They work by mimicking the antibodies your body produces in response to a virus. These molecules are produced in a laboratory and they work to block the COVID-19 virus from entering your cells. Monoclonal antibody treatment is a fluid given using a needle either into a vein (infusion) or under the skin (subcutaneously). Your healthcare provider or the site where you will be getting treatment will explain which treatment you will get. For both procedures, needles are used by a trained medical professional. If you are unvaccinated, you should wait 90 days after your treatment to get the vaccine. Regen-Cov, Sotrovimab, Bebtelovimab and Evusheld are all monoclonal antibodies. Sotrovimab is effective against infection by the  Omicron variant.  Q6: Finally, April is National Minority Health Month how can I get involved? This year the U.S. Department of Health and Human Services (HHS) Office of Minority Health (OMH) and its partners are highlighting the important role community plays in helping to reduce health disparities in racial and ethnic minority and American Indian/Alaska Native groups. The theme for this year is Give Your Community a Boost!  To support COVID-19 vaccination and boosting, OMH invites you to #BoostYourCommunity by using, sharing, and attending National Minority Health Month (NMHM) resources and events with your organization, communities, and network!  If you are not insured, you might qualify for the Oregon Health Plan, which covers COVID-19 vaccines, boosters, treatment and home tests. It also covers regular check-ups, prescriptions, mental health care, addiction treatment, dental care and more. To see if you qualify and to learn more go to OHP.Oregon.gov and click Apply for OHP. You can also call 800-699-9075 or find a local community partner at bit.ly/ohplocalhelp for help.Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or COVID19.LanguageAccess@dhsoha.state.or.us.

In this episode Alin and Colby talk to Dr. Sejal Patel. Sejal is a pancreas and two time kidney transplant recipient. Sejal discusses going through multiple transplants, being on dialysis, and how this changed her career path. Additionally we discuss the pre exposure prophylaxis treatment for Covid 19 named Evusheld. Evusheld is a combination of two monoclonal antibodies that both Sejal and Alin have received. Become a podcaster yourself: https://alitu.com?fp_ref=bothsides

Die Corona-Maßnahmen werden vielerorts gelockert, bei Personen, die ein Risiko für einen schweren Verlauf haben, steigen damit aber die Sorgen. Direkt nach einer Infektion können ihnen Antikörper oder Medikamente wie Evusheld und Paxlovid helfen. Allerdings greifen bei Omikron nicht mehr alle Präparate.Wildermuth, Volkartwww.deutschlandfunk.de, Forschung aktuellDirekter Link zur Audiodatei

Health Minister Andrew Little says anyone who meets the criteria for Covid antiviral drugs will get them, whether they're vaccinated or not. [audio_play] "We have a basic principle in the health system, we don't discriminate on the basis of any factor, that includes those who've chosen not to be vaccinated." Paxlovid has arrived in the country and will be available next week. Doctors prescribing the pills will consider age, disability and whether a person is immunocompromised. Little told Morning Report people will have to see their GP in person to get a prescription. Pharmac has also secured access to the antiviral drug Molnupiravir and preventative medicine Evusheld, both of which still need Medsafe approval.

On Tuesday, the FDA authorized a fourth dose of the Pfizer-BioNTech and Moderna coronavirus vaccines for everyone 50 and older. Plus, the California Supreme Court welcomed its first Latina justice, Patricia Guerrero, formerly a San Diego appellate judge. Then, a newly available drug called Evusheld would help protect people whose immune systems are unable to fight COVID-19, but not everyone who needs it can access the drug. Then, we hear about a childcare program offered to mothers experiencing homelessness through Father Joe's Villages. Finally, a preview of "A Twisted Bargain," a new play opening this weekend at the Tenth Avenue Arts Center which was inspired by the infamous Leopold-Loeb murder case.

AstraZeneca anti-viral drug

- Bệnh viện đa khoa Tâm Anh Hà Nội và Bệnh viện đa khoa Tâm Anh TP.HCM đã chính thức triển khai tiêm kháng thể đơn dòng Evusheld ngừa COVID-19 cho người suy giảm miễn dịch từ vừa đến nặng, người không thể tiêm hoặc đã tiêm vaccine COVID-19 nhưng không sản sinh đủ kháng thể để chống lại SARS-CoV-2. Chủ đề : tiêm kháng thể đơn dòng, Evusheld ngừa COVID-19, người nguy cơ cao --- Support this podcast: https://anchor.fm/vov1tintuc/support

In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Moderna vaccine results in children (Moderna) Delta/Omicron hospitalization by ethnicity (MMWR) Intrinsic BA.2 severity in unvaccinated children (Lancet) Children and COVID state-level data (AAP) Placentitis and thrombohematoma during pregnancy (JAMA) Predictive value of symptoms for diagnosis (Clin Inf Dis) FDA to discuss booster strategy (FDA) Evusheld activity against BA.1 and BA.2 (AstraZeneca and bioRxiv) Remdesivir resistance in immunocompromised patient (Nature Comm) Ivermectin for COVID with and without strongyloidiasis (JAMA) Inhaled ciclesonide for outpatient treatment (Clin Micro Inf) Home telemonitoring for infection (J Telemed Telecare) Effectiveness of pulse oximetry in remote monitoring (Lancet) Effects of anti-platelet therapy (JAMA) COVID deaths in Zambia (medRxiv) Contribute to ASTMH fundraiser at PWB Letters read on TWiV 880 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Moderna vaccine results in children (Moderna) Delta/Omicron hospitalization by ethnicity (MMWR) Intrinsic BA.2 severity in unvaccinated children (Lancet) Children and COVID state-level data (AAP) Placentitis and thrombohematoma during pregnancy (JAMA) Predictive value of symptoms for diagnosis (Clin Inf Dis) FDA to discuss booster strategy (FDA) Evusheld activity against BA.1 and BA.2 (AstraZeneca and bioRxiv) Remdesivir resistance in immunocompromised patient (Nature Comm) Ivermectin for COVID with and without strongyloidiasis (JAMA) Inhaled ciclesonide for outpatient treatment (Clin Micro Inf) Home telemonitoring for infection (J Telemed Telecare) Effectiveness of pulse oximetry in remote monitoring (Lancet) Effects of anti-platelet therapy (JAMA) COVID deaths in Zambia (medRxiv) Contribute to ASTMH fundraiser at PWB Letters read on TWiV 880 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

- Ngày hôm nay (24/3), Hệ thống BV Đa khoa Tâm Anh chính thức nhận bàn giao lô kháng thể đơn dòng Evusheld đầu tiên từ Hệ thống tiêm chủng VNVC và AstraZeneca Việt Nam. Trước đó, kháng thể đơn dòng Evusheld dự phòng Covid-19 đầu tiên đã được Cơ quan quản lý thực phẩm và dược phẩm Hoa Kỳ FDA cấp phép về Việt Nam, là “vũ khí” phòng ngừa và điều trị Covid-19 và kịp thời bảo vệ nhóm người dễ bị tổn thương trước đại dịch. --- Support this podcast: https://anchor.fm/vov1tintuc/support

Overseas travel and COVID - booster before travelling? What's the evidence? The more transmissible OMICRON subvariant... is there any cause for concern here? Pre-exposure Prophylaxis - understanding how to use EVUSHELD - what/when/for who/safety and side effects Which Anti-COVID drugs DO NOT work for OMICRON?...most of the MABs Paed vax programme issues… data suggests rapidly waning protection? Daycare/pre-school challenges Twindemic prep, indigenous update Host: Dr David Lim | Total time: 43 mins Guest: Prof Robert Booy, Infectious Diseases Specialist and Paediatrician; Professor of Paediatrics and Child Health, University of Sydney Clinical School, Children's Hospital at Westmead Register for our fortnightly FREE WEBCASTS Every second Tuesday | 7:00pm-9:00pm AEDT Click here to register for the next one See omnystudio.com/listener for privacy information.

Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM. Help Sonal kick off her 2nd year of podcasting by supporting it!! Sonal's 5th Season begins and Episode 11 features Part 1 of her special Newsworthy session with certified medical biller, Kate Patskovska. Trusty Tip features Sonal's compliance recommendations on the new HCPCS code (Q0221) for EVUSHELD™. Spark inspires us all to reflect on clarity and focus based on the inspirational words of Tony Robbins. Find Kate Patskovska on various social media platforms: LinkedIn: https://www.linkedin.com/in/kate-patskovska-cpb-aapc-approved-instructor-cpb-i-76596918/ Website/Blog: https://kr2billing.com/ On Demand Webinars: https://kr2medicalbilling.thinkific.com/ Paint The Medical Picture Podcast now on: Anchor: https://anchor.fm/sonal-patel5 Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3X Apple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177 Google Podcasts: https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy8zMGYyMmZiYy9wb2RjYXN0L3Jzcw== Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcast Breaker: https://www.breaker.audio/paint-the-medical-picture-podcast Pocket Casts: https://pca.st/tcwfkshx Radio Public: https://radiopublic.com/paint-the-medical-picture-podcast-WRZvAw Find Paint The Medical Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7A Find Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/ And checkout the website: https://paintthemedicalpicturepodcast.com/ If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/sonal-patel5/message Support this podcast: https://anchor.fm/sonal-patel5/support

The Baltimore County Council's revised redistricting map, still draws ire from the local NAACP. Maryland's GOP senators launch a drive for what they say will be ‘meaningful tax relief.' Baltimore City uses millions in ARPA funds to create a jobs training program. Local health systems team up to send medical supplies to Ukraine. The war there continues to drive up gas prices in Maryland and across the country. And a doctor tells us what you need to know about Evusheld, a COVID antibody treatment for the immunocompromised.  See omnystudio.com/listener for privacy information.

In our continuing series looking at the latest medical research and news on COVID-19, Larry Mantle speaks with Dr. Dean Blumberg, professor of medicine and chief of Pediatric Infectious Diseases at UC Davis Children's Hospital.  Topics today include: Worldwide death toll from COVID surpasses 6 million as pandemic enters its third year.  Why have some people never caught COVID? The answers may help protect us all.  L.A. child care providers say mask mandates kept kids safe, and they're not ready to drop them.  Vaccination rates among teens and young adults remain low, as two Southern California teens die of COVID.  Data analysis shows deaths among the vaccinated in California rose sharply with Omicron.  Lack of awareness and limited supply limit rollout of COVID antibody treatment Evusheld.  A surge in cases challenges China's “zero COVID” approach.  This program is made possible in part by the Corporation for Public Broadcasting, a private corporation funded by the American people.   

Presented by New America and Arizona State University, the Coronavirus Weekly Brief concisely breaks down the top headlines you need to know surrounding the novel coronavirus. Follow us on Twitter at @NewAmericaISP and find daily briefs at newamerica.org/international-security/blog/new-america-coronavirus-daily-brief/ Hosts: David Sterman, senior policy analyst for New America's International Security Program Emily Schneider, senior program associate for the International Security Program at New America

Episode 85: Detecting Dementia and Evusheld®. Parneeta Singh explained a new blood test to predict Alzheimer's disease and an artificial-intelligence cognitive test for early detection of dementia. Dr Saito and Dr Arreaza present Evusheld, a monoclonal antibody for pre-exposure prophylaxis against COVID-19.  Today is March 4, 2022. Today marks the 2-year anniversary of our podcast. We have been bringing you relevant clinical information for 2 years, almost every week. We hope you have found this podcast useful. If you have learned at least one thing from us, our goal has been reached. This podcast started as an experiment and it has become an enriching experience for students, residents, faculty, and all of you who listen to us throughout the world. We look forward to many more years of education, updates, and fun! Thanks for listening.Introduction: Innovative ways to detect dementia: Alzosure Predict® and CognICA® By Parneeta Singh, MD, Ross University School of Medicine; comments by Hector Arreaza, MD.   Alzheimer's disease (AD) is a neurocognitive disorder that is the most common cause of dementia. More than 6 million Americans aged 65 and older have the late-onset subtype while many more between ages 30 and 60s have the early-onset subtype although the latter is very rare. One of the first signs of AD is memory issues. A decline in other aspects of thinking, impaired judgment or reasoning, visual/spatial problems can also indicate early stages of AD. Mild cognitive impairment (MCI) can also be considered an early sign of AD. However, not everyone with MCI will develop the disease. As the disease progresses, people with AD have trouble performing daily activities such as cooking, driving, managing their finances while some have personality changes as well. According to the Alzheimer's Association, two abnormal structures called plaques (deposits of a protein fragment called beta-amyloid that builds up between neurons) and tangles (twisted fibers of another protein called tau that builds up inside neurons) are most probably responsible for the damaging effects seen in AD. Patients with AD develop plaques and tangles initially in parts of the brain involved in memory, such as the entorhinal cortex and hippocampus, before affecting other parts of the brain such as the cerebral cortex which is responsible for reasoning, social behavior, and language. Today, AD is at the forefront of biomedical research with earlier diagnoses and interventions improving drastically. New research conducted by Diadem (a diagnostic company that focuses on AD research) exhibited that a novel blood test called Alzosure Predict® identifies a variant of the protein p53 which seems to predict AD's progression up to 6 years before a clinical diagnosis is made. This blood test measures a derivative of p53 (U-p53AZ) which is implicated in AD pathogenesis. Blood samples from patients aged 60 years and older who had different levels of cognitive function were analyzed which showed that the test predicted a decline from MCI to AD at the end of 6 years. The test can also classify a patient's cognition stage. The positive predictive value (PPV) and negative predictive value (NPV) were at 90%. Knowing which patients will progress to AD allows them to try treatments earlier on the disease when therapies are most likely to be more effective. Additionally, using the test could speed up the approval of prospective drug treatments and allow those patients with a likelihood of developing AD to enroll in clinical studies. Patients can also be monitored during a study instead of relying on costly PET scans and painful lumbar punctures. These findings were presented at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2021.Another way to detect dementia early on is by an artificial intelligence cognitive assessment called Cognetivity's Integrated Cognitive Assessment (CognICA®) which has been cleared by the US Food and Drug Administration in October 2021. It is a 5-minute computerized cognitive assessment that is completed using an iPad. It has numerous advantages over traditional pen and paper-based cognitive tests such as avoidance of cultural or educational bias, absence of learning effect upon repeat testing, its high sensitivity to detect early-stage cognitive impairment, and since it is computer-based, it can be self-administered and performed remotely. In conclusion, reliable, simple, cost-effective measures of cognition are critical for providing quality care whether it is in the field of family medicine, neurology, or geriatrics. According to Percy Griffin, Ph.D., MSc, director of scientific engagement at the Alzheimer's Association, the ability of such technologies to detect dementia before significant loss of brain cells “would be game-changing” for individuals, their families, and the healthcare system at large. This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. ___________________________Evusheld. Written by Brandy Truong, MS4, Ross University School of Medicine. Edited by Hector Arreaza, MD. Collaboration: Steven Saito, MD.This monoclonal antibody is for pre-exposure prophylaxis (PrEP) of COVID-19, which means it is given prior to exposure to the virus. Evusheld is not a replacement for COVID-19 vaccines, and everyone eligible to receive one of the safe and effective COVID-19 vaccines should do so.It is meant to give protection to those who are unable to mount an adequate immune response against COVID 19 after vaccination. It was given an emergency authorization use by FDA on December 8, 2021. EVUSHELD is tixagevimab co-packaged with cilgavimab, two long-acting antibodies. This medication may be effective for pre-exposure prevention up to six months.It was designed to be given to the immunocompromised population and for anyone who cannot receive the vaccine, as long as the patient is older than 12 years and more than 88 pounds.  (We totally make the cut). If your patient has a health condition that won't allow their immune system to develop a strong enough response to the COVID-19 vaccine, for example, they are immunocompromised because of cancer, they can receive Evusheld. If they are taking medications that prevent a strong enough response to the COVID-19 vaccine, for example, chemotherapy or transplant anti-rejection medications, they can receive Evusheld.If they are unable to get the vaccine due to anaphylaxis to all of the COVID-19 vaccines or their ingredients, they can receive Evusheld.Monoclonal antibodies are lab-made proteins that mimic the immune system's way of fighting off infections. The two antibodies in Evusheld are long-acting and are made to specifically fight off against SARS-CoV-2. Evusheld is administered by two injections immediately given one after another.In a recent study done looking at how effective Evusheld was, it showed a 77% reduced risk of developing COVID-19 compared to individuals who received placebo. This study was a randomized, double-blind, placebo-controlled trial in adults older than 59 years old or with a prespecified chronic medical condition or at increased risk for COVID-19 and for other reasons didn't receive the vaccine and have no prior history of COVID-19. Some side effects of the medication include hypersensitivity reactions, bleeding at injection site, headache, fatigue, and cough. If you would like to provide this monoclonal antibody Evusheld to your patients, as well as other treatments such as Paxlovid, Molnupiravir, sotrovimab, and bebtelovimab, consult the COVID-19 Therapeutics Locator provided by the office of the Assistant Secretary for Preparedness & Response. You can do a Google search for HHS COVID-19 Therapeutics locator or you can find the link in the notes of this episode. [https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/]________________________________Now we conclude our episode number 85 “Detecting Dementia and Evusheld” You listened to Dr Singh present some new promising ways to recognize Alzheimer's disease early and detect those who are at risk of progression. We are all hoping for a simple way to diagnose Alzheimer's, and in the near future, we may have a blood test that can help us diagnose this devastating disease. Also, you heard about Evusheld, the new monoclonal antibody given Emergency Use Authorization by FDA for pre-exposure prophylaxis for COVID-19. Consult the Therapeutics Locator to see the availability in your area. Even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created for educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Parneeta Singh, Brandy Truong, and Steven Saito. Audio edition: Suraj Amrutia. See you next week!  References:Alzheimer's Association: What is Alzheimer's Disease? https://www.alz.org/alzheimers-dementia/what-is-alzheimers, accessed on 30 December 2021.  National Institute of Aging: What is Alzheimer's Disease? https://www.nia.nih.gov/health/what-alzheimers-disease, accessed on December 30, 2021.  New Blood Test May Detect Preclinical Alzheimer's Years in Advance, https://www.medscape.com/viewarticle/963509?uac=242448MJ&faf=1&sso=true&impID=3825884&src=WNL_trdalrt_211126_MSCPEDIT#vp_1, accessed on 30 December, 2021. FDA Clears 5-Minute Test for Early Dementia, https://www.medscape.com/viewarticle/961277?uac=242448MJ&faf=1&sso=true&impID=3729166&src=wnl_newsalrt_211020_MSCPEDIT, accessed on 30 December, 2021. Cognetivity Neurosciences, https://cognetivity.com/cognica/, accessed on December 30, 2021.  Evusheld Antibody Treatment for COVID-19 High-risk Groups, South Carolina Department of Health and Environmental Control, December 8, 2021, https://scdhec.gov/covid19/monoclonal-antibodies/evusheld-antibody-treatment-covid-19-high-risk-groups. HHS Therapeutics Locator, office of the Assistant Secretary for Preparedness & Response,  https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

Here's how we're doing. COVID is continuing to subside around the world with a weekly 16% decrease in deaths and 15% decrease in cases since Omicron first showed up. However, Asia's infections rose 4% and deaths were only down 0.9% with South Korea, Indonesia, Vietnam and Hong Kong setting daily records last week. In fact, Hong Kong recorded 26,026 cases after never going above 100 every day until this year. New Zealand is also hitting five digits in cases for the first time.The FDA revised the emergency use authorization for Evusheld, a monoclonal antibody against Covid for immunocompromised people and those who can't be vaccinated for medical reasons. They now say you need twice the dose that's been being given. Those who already got the drug are being told to go back and get another injection as soon as possible. The agency said protection against symptomatic disease may not last as long as was shown in clinical trials since that was before the Omicron sub-variants emerged.What perfect timing! Face coverings are now optional for the US President's State of the Union address tomorrow. Congress is lifting its mask requirement on the House floor after the CDC eased guidelines last week. DC is now considered low risk based on the new metrics of what's happening in area hospitals. Of course, anyone who wants to can still mask up while listening to the speech.Things continue to loosen up in New York too. The statewide masking requirement in schools will be lifted by March 2. And New York City's Mayor is thinking about lifting vaccine mandates on restaurants, bars, and theaters by early next week. A mask mandate on the city's approximately 1 million schoolchildren could also be lifted. Again, any parent who wants to keep their kid masked can keep them masked. Oh boy, free (meaning paid for by taxpayers) COVID tests for everyone! But it's turning out to be one of the few free things that isn't wanted. Nearly half of the 500 million free tests still haven't been claimed. On day one there were over 45 million orders. After that, not so much. Less than 100,000 orders a day are coming in. Critics say the program would have been immensely helpful before the pandemic was largely over. In the United States, cases were down 63%, deaths are down 24%, and hospitalizations are down 44% over 14 days. The 7-day average of new cases has been trending down since January 14. The five states that had the most daily deaths per 100,000 are Ohio, West Virginia, Maine, Tennessee, and Missouri. There are 26,401,648 active cases in the United States.The top 10 areas with the highest number of recent cases per capita according to The New York Times: Manassas Park, VA. Nome Census Area, AK. Perry, KY. Elmore, ID. Fayette, AL. Linn, MO. Morgan, KY. Aroostook, ME. Ada, ID. And Gooding, ID. There have been 948,398 deaths in the U.S. recorded as COVID-related.The top 3 vaccinating states by percentage of population that's been fully vaccinated: Rhode Island at 80.6%, Vermont at 80.1%, and Maine at 78.3%. The bottom 3 vaccinating states are Alabama at 50.2%, Wyoming at 50.6%, and Mississippi at 50.9%. The percentage of the U.S. that's been fully vaccinated is 64.9%.Globally, cases were down 36% and deaths down 20% over 14 days, with the 7-day average trending down since January 25. There are 63,676,869 active cases around the world.The five countries with the most new cases: South Korea 163,558. Russia 116,093. Germany 95,241. Vietnam 86,990. And Japan 69,661. There have been 5,948,460 deaths reported as Covid-related worldwide. See acast.com/privacy for privacy and opt-out information.

Here's how we're doing. COVID is continuing to subside around the world with a weekly 16% decrease in deaths and 15% decrease in cases since Omicron first showed up. However, Asia's infections rose 4% and deaths were only down 0.9% with South Korea, Indonesia, Vietnam and Hong Kong setting daily records last week. In fact, Hong Kong recorded 26,026 cases after never going above 100 every day until this year. New Zealand is also hitting five digits in cases for the first time.The FDA revised the emergency use authorization for Evusheld, a monoclonal antibody against Covid for immunocompromised people and those who can't be vaccinated for medical reasons. They now say you need twice the dose that's been being given. Those who already got the drug are being told to go back and get another injection as soon as possible. The agency said protection against symptomatic disease may not last as long as was shown in clinical trials since that was before the Omicron sub-variants emerged.What perfect timing! Face coverings are now optional for the US President's State of the Union address tomorrow. Congress is lifting its mask requirement on the House floor after the CDC eased guidelines last week. DC is now considered low risk based on the new metrics of what's happening in area hospitals. Of course, anyone who wants to can still mask up while listening to the speech.Things continue to loosen up in New York too. The statewide masking requirement in schools will be lifted by March 2. And New York City's Mayor is thinking about lifting vaccine mandates on restaurants, bars, and theaters by early next week. A mask mandate on the city's approximately 1 million schoolchildren could also be lifted. Again, any parent who wants to keep their kid masked can keep them masked. Oh boy, free (meaning paid for by taxpayers) COVID tests for everyone! But it's turning out to be one of the few free things that isn't wanted. Nearly half of the 500 million free tests still haven't been claimed. On day one there were over 45 million orders. After that, not so much. Less than 100,000 orders a day are coming in. Critics say the program would have been immensely helpful before the pandemic was largely over. In the United States, cases were down 63%, deaths are down 24%, and hospitalizations are down 44% over 14 days. The 7-day average of new cases has been trending down since January 14. The five states that had the most daily deaths per 100,000 are Ohio, West Virginia, Maine, Tennessee, and Missouri. There are 26,401,648 active cases in the United States.The top 10 areas with the highest number of recent cases per capita according to The New York Times: Manassas Park, VA. Nome Census Area, AK. Perry, KY. Elmore, ID. Fayette, AL. Linn, MO. Morgan, KY. Aroostook, ME. Ada, ID. And Gooding, ID. There have been 948,398 deaths in the U.S. recorded as COVID-related.The top 3 vaccinating states by percentage of population that's been fully vaccinated: Rhode Island at 80.6%, Vermont at 80.1%, and Maine at 78.3%. The bottom 3 vaccinating states are Alabama at 50.2%, Wyoming at 50.6%, and Mississippi at 50.9%. The percentage of the U.S. that's been fully vaccinated is 64.9%.Globally, cases were down 36% and deaths down 20% over 14 days, with the 7-day average trending down since January 25. There are 63,676,869 active cases around the world.The five countries with the most new cases: South Korea 163,558. Russia 116,093. Germany 95,241. Vietnam 86,990. And Japan 69,661. There have been 5,948,460 deaths reported as Covid-related worldwide. See acast.com/privacy for privacy and opt-out information.

This week Dr. Cruse talks about the improving but still high numbers here. He talks about Wallenpaupack school district ending their mask mandate which he thinks is a little too soon. He also talks about a new monoclonal antibody therapy called Evusheld that is is available at Wayne Memorial Community Health Centers to prevent COVID infection in people with severe immune suppression such that they are unlikely to get adequate protection from the vaccine, or for people that are allergic to the vaccine. However it does carry significant cardiac risk and should be used in caution and people at high risk for heart disease.

On Health Suites, AstraZeneca has signed a new purchase agreement with the government of Singapore to deliver Evusheld, its long-acting antibody (LAAB) combination candidate, for the treatment of COVID-19. With the supply expected to arrive in Singapore by year end, Claressa Monteiro speaks to Vinod Narayanan, Country President, AstraZeneca Singapore, to find out more about Evusheld.       See omnystudio.com/listener for privacy information.

The Omicron variant is by far the most dominant of the COVID virus strains in our region at this time. Dr. John Zurlo, Chief of Infectious Diseases updates us on what we're seeing in the hospitals, new monoclonal antibody therapies Sotrovimab and Evusheld, and the accuracy of at-home tests. Plus, he addresses whether the United States will follow in the footsteps of Germany and Israel and expedite an additional booster. Be sure to check out The Health Nexus for additional content on COVID like an update on boosters, floosters, and the omicron variant.   Follow Jefferson Health: @TJUHospital on Twitter @JeffersonHealth on Instagram @JeffersonHospital on Facebook    

En otras noticias: Comerciantes y residentes del Downtown de Miami están afectados por inundaciones desde la noche del martes y piden soluciones urgentes.Policía de Broward presentaron un plan para prevenir accidentes por motociclistas imprudentes durante las tradicionales celebraciones de Martin Luther King.Evusheld: nuevo tratamiento para combatir al coronavirus para personas inmunodeprimidas.

122121 Podcast, Reject Vax passports and mandates, Evusheld, Open Border Terrorists, Fentanyl, COVID Illegals

Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.

This week we bring you up to speed on a lot of COVID-related news, despite the emergence of Omicron, there is positive news; Evusheld has become the first pre-exposure prophylaxis for COVID-19; Data shows that the Pfizer-BioNTech booster dose offers protection against Omicron; Monoclonal antibody therapy is authorized for kids; Heterologous boosting may be more beneficial than homogeneous; and important info about some Veklury lots being recalled.

Evusheld is approved as a preventive treatment against COVID for patients with specific risks for COVID. --- Send in a voice message: https://anchor.fm/covidupdates/message

Trainiere dein Hörverstehen mit den Nachrichten der Deutschen Welle von Donnerstag – als Text und als verständlich gesprochene Audio-Datei.Scholz will Außenpolitik gemeinsam mit Baerbock gestalten Bundeskanzler Olaf Scholz will die Außenpolitik seiner Regierung im Einvernehmen mit Außenministerin Annalena Baerbock von den Grünen gestalten. Die Regierung arbeite gemeinsam "für unser Land", und man werde auch in der Außen- oder Europapolitik gemeinsam agieren, sagte Scholz. Die Grundlagen für die Außenpolitik stünden im Koalitionsvertrag. SPD-Fraktionschef Rolf Mützenich hatte zuvor im Deutschlandfunk erklärt, die deutsche Außenpolitik werde "insbesondere im Kanzleramt" gesteuert. Dem widersprach ausdrücklich der Grünen-Abgeordnete Omid Nouripour, der sich um den Parteivorsitz bewirbt. Weitere Hongkonger Bürgerrechtler verurteilt Drei weitere prominente Hongkonger Bürgerrechtler sind wegen Teilnahme an einem Gedenken an die Opfer der Niederschlagung der Demokratiebewegung 1989 in China verurteilt worden. Außer dem inhaftierten Verleger Jimmy Lai wurden die Anwältin Chow Hang-Tung sowie die Aktivistin Gwyneth Ho schuldig gesprochen. Das Strafmaß soll am kommenden Montag verkündet werden. Die drei waren die letzten von insgesamt 24 Aktivisten und früheren Politikern, die im Zusammenhang mit der - offiziell verbotenen - Kerzenandacht im vergangenen Jahr im Hongkonger Victoria-Park verurteilt wurden. US-Repräsentantenhaus beschließt Importverbot von Produkten aus Xinjiang Die USA wollen wegen der Unterdrückung der muslimischen Minderheit der Uiguren weitere Sanktionen gegen China auf den Weg bringen. Das Repräsentantenhaus verabschiedete ein Gesetz zum Verbot von Importen aus der chinesischen Region Xinjiang wegen Zwangsarbeit. Die Vorlage geht davon aus, dass alle Waren aus Xinjiang durch Zwangsarbeit hergestellt werden. Damit das Gesetz in Kraft treten kann, muss es noch den Senat passieren. Aus Xinjiang stammt ein Großteil der weltweiten Materialien für Solarzellen. Menschenrechtsgruppen werfen China die Unterdrückung der Uiguren in der Region Xinjiang vor. Ministerpräsident von Burkina Faso tritt zurück Nach Protesten wegen der anhaltenden Gewalt von Terrormilizen ist in Burkina Faso Ministerpräsident Christophe Marie Joseph Dabiré zurückgetreten. Ein entsprechendes Dekret von Präsident Roch Marc Christian Kaboré wurde im staatlichen Fernsehen verlesen. Dabiré soll jedoch weiter amtieren, bis eine neue Regierung gebildet worden ist. In der Hauptstadt Ouagadougou gibt es immer wieder Demonstrationen, bei denen der Regierung "Unfähigkeit" im Kampf gegen die Dschihadisten vorgeworfen wird. Seit 2016 wurden bei Angriffen etwa 2000 Menschen getötet. 1,4 Millionen Menschen flohen vor der Gewalt. USA lassen Medikament mit künstlichen Corona-Antikörpern zu Die US-Gesundheitsbehörden haben ein Medikament mit synthetischen Antikörpern zugelassen, das Menschen vor einer Corona-Infektion schützen soll. Die Arzneimittelbehörde FDA erteilte eine Notfallzulassung für das von AstraZeneca entwickelte Präparat Evusheld. Die Behörde warnte allerdings, das Medikament sei kein Ersatzpräparat für Menschen, bei denen die Impfung empfohlen werde. Es dürfe nur eingesetzt werden bei Menschen mit einem geschwächten Immunsystem oder solchen, die aus medizinischen Gründen wie einer starken allergischen Reaktion gegen Vakzine nicht geimpft werden können. Bayern München im Achtelfinale der Champions League Fußball-Bundesligist Bayern München ist nach starker Leistung in das Achtelfinale der Champions League eingezogen. Im sechsten Gruppenspiel gelang dem deutschen Rekordmeister gegen den FC Barcelona ein 3:0 und damit der sechste Sieg. Der VfL Wolfsburg scheiterte dagegen in der Gruppenphase und darf auch in der Europa League nicht weiterspielen. Die Niedersachsen verloren gegen den französischen Meister OSC Lille mit 1:3 und schlossen die Vorrundengruppe G auf dem vierten und letzten Platz ab.